PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Gabay, Cem
TI  - 24-Week Data from the Phase 4 ADACTA Trial
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 10--11
VI  - 12
IP  - 9
4099  - http://mdc.sagepub.com/content/12/9/10.short
4100  - http://mdc.sagepub.com/content/12/9/10.full
AB  - Results from the Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis trial [ADACTA; NCT01119859], suggest that tocilizumab monotherapy may be more effective than adalimumab monotherapy reducing the signs and symptoms of rheumatoid arthritis.